These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

362 related articles for article (PubMed ID: 24374844)

  • 21. Factors affecting the accuracy of anti-BRAF V600E immunohistochemistry results in ameloblastomas.
    Chang JYF; Lu PH; Tseng CH; Wang YP; Lee JJ; Chiang CP
    J Oral Pathol Med; 2023 Apr; 52(4):342-350. PubMed ID: 36625499
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Research advances in the v-raf murine sarcoma viral oncogene homolog gene mutation in ameloblastoma].
    Yan XC; Sun LS; Dong ZW; You Z; Dong Q
    Zhonghua Kou Qiang Yi Xue Za Zhi; 2018 Jul; 53(7):500-502. PubMed ID: 29996373
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Frequency of BRAF V600E mutation in a group of Thai patients with ameloblastomas.
    Lapthanasupkul P; Laosuk T; Ruangvejvorachai P; Aittiwarapoj A; Kitkumthorn N
    Oral Surg Oral Med Oral Pathol Oral Radiol; 2021 Nov; 132(5):e180-e185. PubMed ID: 32665205
    [TBL] [Abstract][Full Text] [Related]  

  • 24. DNA damage response activation and cell cycle dysregulation in infiltrative ameloblastomas: A proposed model for ameloblastoma tumor evolution.
    Diniz MG; Guimarães BVA; Pereira NB; de Menezes GHF; Gomes CC; Gomez RS
    Exp Mol Pathol; 2017 Jun; 102(3):391-395. PubMed ID: 28454892
    [No Abstract]   [Full Text] [Related]  

  • 25. Reversible and adaptive resistance to BRAF(V600E) inhibition in melanoma.
    Sun C; Wang L; Huang S; Heynen GJ; Prahallad A; Robert C; Haanen J; Blank C; Wesseling J; Willems SM; Zecchin D; Hobor S; Bajpe PK; Lieftink C; Mateus C; Vagner S; Grernrum W; Hofland I; Schlicker A; Wessels LF; Beijersbergen RL; Bardelli A; Di Nicolantonio F; Eggermont AM; Bernards R
    Nature; 2014 Apr; 508(7494):118-22. PubMed ID: 24670642
    [TBL] [Abstract][Full Text] [Related]  

  • 26. High frequency of BRAF V600E mutation in Iranian population ameloblastomas.
    Derakhshan S; Aminishakib P; Karimi A; Saffar H; Abdollahi A; Mohammadpour H; Kharazi Fard MJ; Memarha A
    Med Oral Patol Oral Cir Bucal; 2020 Jul; 25(4):e502-e507. PubMed ID: 32388526
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Lung cancers with acquired resistance to EGFR inhibitors occasionally harbor BRAF gene mutations but lack mutations in KRAS, NRAS, or MEK1.
    Ohashi K; Sequist LV; Arcila ME; Moran T; Chmielecki J; Lin YL; Pan Y; Wang L; de Stanchina E; Shien K; Aoe K; Toyooka S; Kiura K; Fernandez-Cuesta L; Fidias P; Yang JC; Miller VA; Riely GJ; Kris MG; Engelman JA; Vnencak-Jones CL; Dias-Santagata D; Ladanyi M; Pao W
    Proc Natl Acad Sci U S A; 2012 Jul; 109(31):E2127-33. PubMed ID: 22773810
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR.
    Prahallad A; Sun C; Huang S; Di Nicolantonio F; Salazar R; Zecchin D; Beijersbergen RL; Bardelli A; Bernards R
    Nature; 2012 Jan; 483(7387):100-3. PubMed ID: 22281684
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Advancements in MAPK signaling pathways and MAPK-targeted therapies for ameloblastoma: A review.
    You Z; Liu SP; Du J; Wu YH; Zhang SZ
    J Oral Pathol Med; 2019 Mar; 48(3):201-205. PubMed ID: 30489659
    [TBL] [Abstract][Full Text] [Related]  

  • 30. High prevalence of BRAF V600E mutations in Korean patients with ameloblastoma: Clinicopathological significance and correlation with epithelial-mesenchymal transition.
    Oh KY; Cho SD; Yoon HJ; Lee JI; Ahn SH; Hong SD
    J Oral Pathol Med; 2019 May; 48(5):413-420. PubMed ID: 30889301
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Molecular pathogenesis of ameloblastoma.
    Marín-Márquez C; Kirby J; Hunter KD
    J Oral Pathol Med; 2024 May; 53(5):277-293. PubMed ID: 38664938
    [TBL] [Abstract][Full Text] [Related]  

  • 32. BRAF V600E mutation detected in cell-free DNA from conventional ameloblastomas fluid aspirate.
    Martins-de-Barros AV; Barros AMI; Lazo RJGS; Barbosa Neto AG; Araújo FADC; Carvalho MV
    Oral Dis; 2024 Sep; 30(6):3962-3965. PubMed ID: 38168084
    [No Abstract]   [Full Text] [Related]  

  • 33. Clinical significance of BRAF non-V600E mutations on the therapeutic effects of anti-EGFR monoclonal antibody treatment in patients with pretreated metastatic colorectal cancer: the Biomarker Research for anti-EGFR monoclonal Antibodies by Comprehensive Cancer genomics (BREAC) study.
    Shinozaki E; Yoshino T; Yamazaki K; Muro K; Yamaguchi K; Nishina T; Yuki S; Shitara K; Bando H; Mimaki S; Nakai C; Matsushima K; Suzuki Y; Akagi K; Yamanaka T; Nomura S; Fujii S; Esumi H; Sugiyama M; Nishida N; Mizokami M; Koh Y; Abe Y; Ohtsu A; Tsuchihara K
    Br J Cancer; 2017 Nov; 117(10):1450-1458. PubMed ID: 28972961
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Association of MDM2 Overexpression in Ameloblastomas with
    Tosios KI; Kalogirou EM; Koutlas IG
    Int J Mol Sci; 2024 Feb; 25(4):. PubMed ID: 38396916
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Neoadjuvant BRAF-targeted therapy for ameloblastoma of the mandible: an organ preservation approach.
    Grynberg S; Vered M; Shapira-Frommer R; Asher N; Ben-Betzalel G; Stoff R; Steinberg Y; Amariglio N; Greenberg G; Barshack I; Toren A; Yahalom R; Schachter J; Rechavi G; Hirschhorn A; Abebe Campino G
    J Natl Cancer Inst; 2024 Apr; 116(4):539-546. PubMed ID: 37966914
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Discovery of novel molecular characteristics and cellular biological properties in ameloblastoma.
    Kondo S; Ota A; Ono T; Karnan S; Wahiduzzaman M; Hyodo T; Lutfur Rahman M; Ito K; Furuhashi A; Hayashi T; Konishi H; Tsuzuki S; Hosokawa Y; Kazaoka Y
    Cancer Med; 2020 Apr; 9(8):2904-2917. PubMed ID: 32096304
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Adenoid Ameloblastoma with BRAF p.V600E Mutation Revealing Ameloblastomatous Origin: A First Case Report.
    Noda Y; Sawada S; Sakagami T; Kojima Y; Higasa K; Tsuta K
    Head Neck Pathol; 2023 Sep; 17(3):788-792. PubMed ID: 37093491
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The importance of BRAF-V600E mutation to ameloblastoma metabolism.
    Duarte-Andrade FF; Silva AMB; Vitório JG; Canuto GAB; Costa SFS; Diniz MG; Fernandes AP; de Toledo JS; André LC; Gomes CC; Gomez RS; Fonseca FP
    J Oral Pathol Med; 2019 Apr; 48(4):307-314. PubMed ID: 30739334
    [TBL] [Abstract][Full Text] [Related]  

  • 39. BRAF inhibitors in BRAF V600E-mutated ameloblastoma: systematic review of rare cases in the literature.
    Ebeling M; Scheurer M; Sakkas A; Pietzka S; Schramm A; Wilde F
    Med Oncol; 2023 Apr; 40(6):163. PubMed ID: 37115331
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Assessment of BRAFV600E and SMOF412E mutations in epithelial odontogenic tumours.
    Diniz MG; Gomes CC; Guimarães BV; Castro WH; Lacerda JC; Cardoso SV; de Faria PR; Dias FL; Eisenberg AL; Loyola AM; Gomez RS
    Tumour Biol; 2015 Jul; 36(7):5649-53. PubMed ID: 25854168
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.